{"id":429863,"date":"2019-09-19T08:04:01","date_gmt":"2019-09-19T08:04:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=429863"},"modified":"2019-09-19T08:04:01","modified_gmt":"2019-09-19T08:04:01","slug":"nucleic-acidbased-therapeutics-market-trends-size-technology-growth-key-players-future-scope-global-opportunity-and-regional-industry-share-analysis-2019-2022","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nucleic-acidbased-therapeutics-market-trends-size-technology-growth-key-players-future-scope-global-opportunity-and-regional-industry-share-analysis-2019-2022_429863.html","title":{"rendered":"Nucleic Acid-Based Therapeutics Market \u2013 Trends, Size, Technology Growth, Key Players, Future Scope, Global Opportunity and Regional Industry Share Analysis 2019 – 2022"},"content":{"rendered":"
\"Nucleic<\/a><\/p>\n
\n
Nucleic Acid-Based Therapeutics Market <\/div>\n<\/div>\n<\/div>\n
Nucleic Acid-based Therapeutics Market Research by Technology (Anti-Sense and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers and Others), by Applications (Monogenetic disorders (Thalassemia, Sickle cell anemia, Hemophilia, Cystic Fibrosis etc.) and Multi-genetic disorders (Cancer, Diabetes, Neurodegenerative Diseases, cardiovascular Diseases etc.)) and by End Users (Hospitals, Academic & Research Institutes) – Forecast till 2022<\/div>\n

Nucleic acid-based therapeutics are target deficiencies or dysfunctions at the molecular level and are targeted therapies. These are used specifically to target genetic diseases and disorders for which there exists no permanent cure such as thalassemia, sickle cell anemia, hemophilia, cystic fibrosis, diabetes etc.<\/span><\/strong><\/p>\n

Market Overview<\/strong><\/p>\n

Nucleic acid-based therapeutics are used to target genes responsible for either the expression of a disease causing proteins or to correct the decreased protein expression in diseases where the absence of the protein contributes to a disease state<\/p>\n

The global Nucleic Acid-based Therapeutics Market is expected to reach around USD 741.98 million by the end of the forecast period and is expected to grow at a CAGR of ~6.8%.<\/p>\n

The critical market driver for nucleic acid-based therapies is the poor cure rates for genetic diseases with traditional drugs. Other market drivers include increasing understanding of the human genetics, growing capabilities of mapping human tissue molecular targets, rising power of software’s to mimic the human molecular entities such as receptors etc.<\/p>\n

Request a Free Sample at https:\/\/www.marketresearchfuture.com\/sample_request\/2978<\/a><\/strong><\/p>\n

The “<\/strong>Nucleic Acid-Based Therapeutics Market” are based on accurate target identification and genetic profiling and the human gene project has formed the backbone of these class of drugs. As such nucleic acid-based medication have one of the most versatile and revolutionary potential.<\/p>\n

Competitive Analysis:<\/strong><\/p>\n

Some of the key players in this market are: Wave Life Sciences Ltd., Copernicus Therapeutics Inc., Imugene, Caperna, Phylogica, Protagonist Therapeutics, Benitec Biopharma, EGEN (Expression Genetics), Benitec Biopharma, BioMedica (Oxford BioMedica), Transgene and others.<\/strong><\/p>\n

Company Profile<\/strong><\/p>\n

10.1 Wave Life Sciences Ltd., Copernicus Therapeutics Inc.<\/p>\n

10.1.1 Company Overview<\/p>\n

10.1.2 Product\/Business Segment Overview<\/p>\n

10.1.3 Financials<\/p>\n

10.1.4 Key Developments<\/p>\n

10.1.5 SWOT Analysis<\/p>\n

10.2 Imugene<\/p>\n

10.2.1 Overview<\/p>\n

10.2.2 Product\/Business Segment Overview<\/p>\n

10.2.3 Financials<\/p>\n

10.2.4 Key Developments<\/p>\n

10.2.5 SWOT Analysis<\/p>\n

10.3 Caperna<\/p>\n

10.3.1 Overview<\/p>\n

10.3.2 Product\/Business Segment Overview<\/p>\n

10.3.3 Financials<\/p>\n

10.3.4 Key Developments<\/p>\n

10.3.5 SWOT Analysis<\/p>\n

10.4 Phylogica<\/p>\n

10.4.1 Overview<\/p>\n

10.4.2 Product\/Business Segment Overview<\/p>\n

…And Many More.<\/p>\n

Nucleic Acid-Based Therapeutics Market Segmentation:<\/strong><\/p>\n

Global nucleic acid-based therapeutics market has been segmented on the basis of technology<\/span> which comprises anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers and others.<\/p>\n

On the basis of applications<\/span>; market is segmented into monogenetic disorders which is further sub segmented into thalassemia, sickle cell anemia, hemophilia, cystic fibrosis etc. and multi-genetic disorders which is sub segmented into cancer, diabetes, neurodegenerative diseases, cardiovascular diseases etc.<\/p>\n

On the basis of end users<\/span>; market is segmented into hospitals, academic & research institutes.<\/p>\n

Browse Complete Premium Research Report along with List of Table, Figures and Table of Content at <\/strong>https:\/\/www.marketresearchfuture.com\/reports\/nucleic-acid-based-therapeutics-market-2978<\/a><\/strong><\/p>\n

Regional Analysis:<\/strong><\/p>\n

Globally America is the largest market for nucleic acid-based therapeutics. The presence of strong research base, excellent reimbursement scenario, the good provisions for orphan diseases and drugs and the rapid uptake of new drugs and technology are the prime reasons for this dominance. Europe is the second-largest market for nucleic acid-based therapeutics. The developed markets are likely to maintain their leads due to the nonexistence of regulatory framework in the developing and poor regions of the world such as Asia pacific region and Africa.<\/p>\n

List Of Tables<\/strong><\/p>\n

TABLE 1 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, 2013-2022 (USD MILLION)<\/p>\n

TABLE 2 GLOBAL NUCLEIC ACID- BASED THERAPEUTICS MARKET, BY TECHNOLOGY, 2013-2022 (USD MILLION)<\/p>\n

TABLE 3 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY APPLICATIONS, 2013-2022 (USD MILLION)<\/p>\n

TABLE 4 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY END USER, 2013-2022 (USD MILLION)<\/p>\n

TABLE 5 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY REGION, 2013-2022 (USD MILLION)<\/p>\n

…To be Continued.<\/p>\n

About Market Research Future: <\/strong>we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.<\/p>\n

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.<\/p>\n

Contact:<\/p>\n

Market Research Future<\/p>\n

+1 646 845 9312<\/p>\n

Email: sales@marketresearchfuture.com<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Market Research Future<\/a>
Contact Person:<\/strong> Abhishek Sawant
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9312
Address:<\/strong>Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> https:\/\/www.marketresearchfuture.com\/reports\/nucleic-acid-based-therapeutics-market-2978<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Nucleic Acid-Based Therapeutics Market Nucleic Acid-based Therapeutics Market Research by Technology (Anti-Sense and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers and Others), by Applications (Monogenetic disorders (Thalassemia, Sickle cell anemia, Hemophilia, Cystic Fibrosis etc.) and Multi-genetic … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,420],"tags":[],"class_list":["post-429863","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/429863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=429863"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/429863\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=429863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=429863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=429863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}